179420-77-0

Basic information

• Product Name: 4-(3-BROMOPHENYL)TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID
• Synonyms: 4-(3-BROMOPHENYL)OXANE-4-CARBOXYLIC ACID;4-(3-BROMOPHENYL)TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID
• CAS NO: 179420-77-0
• Molecular Formula: C₁₂H₁₃BrO₃
• Molecular Weight: 285.136
• Mol File: 179420-77-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(3-BROMOPHENYL)TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-BROMOPHENYL)TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID(179420-77-0)
• EPA Substance Registry System: 4-(3-BROMOPHENYL)TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID(179420-77-0)

Safety Data

• Hazardous Substances Data: 179420-77-0(Hazardous Substances Data)

Usage

Uses

Used in Medicinal and Pharmaceutical Research:
4-(3-BROMOPHENYL)TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID is utilized as a building block for the synthesis of various heterocyclic compounds and drug candidates. Its structural features contribute to the development of new pharmaceutical agents with potential therapeutic applications.
Used in Organic Synthesis:
In the realm of organic synthesis, 4-(3-BROMOPHENYL)TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID serves as a versatile intermediate for the preparation of complex organic molecules. Its presence allows for the creation of a wide array of chemical entities with diverse functional groups and properties.
Used in Chemical Research:
4-(3-BROMOPHENYL)TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID is also employed in chemical research to explore its reactivity and selectivity in specific chemical transformations. This helps in understanding the underlying mechanisms and potentially discovering new synthetic pathways for the production of novel compounds.

Upstream product

• 14062-30-7 ethyl 2-(3-bromophenyl)acetate 
• 944924-92-9 4-(3-bromo-phenyl)-tetrahydro-pyran-4-carboxylic acid methyl ester 

Downstream Products

• 179420-79-2 4-(3-methylsulfanyl-phenyl)-tetrahydro-pyran-4-carboxylic acid 
• 179420-81-6 methyl 4-(3-mercaptophenyl)-3,4,5,6-tetrahydro-2H-pyran-4-carboxylate 
• 179420-80-5 4-(3-methylsulfanyl-phenyl)-tetrahydro-pyran-4-carboxylic acid methyl ester 
• 179420-78-1 methyl 4-(3-methylsulfinylphenyl)-3,4,5,6-tetrahydro-2H-pyran-4-carboxylate 
• 179420-54-3 4-{3-[4-(2-methyl-1H-imidazol-1-yl)phenylthio]phenyl}-3,4,5,6-tetrahydro-2H-pyran-4-carboxylic acid 
• 179420-53-2 ethyl 4-{3-[4-(2-methyl-1H-imidazol-1-yl)phenylthio]phenyl}-3,4,5,6-tetrahydro-2H-pyran-4-carboxylate 
• 179420-17-8 4-[3-[4-(2-methylimidazol-1-yl)phenylthio]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide 
• 885068-71-3 3-(4-tetrahydro-pyran-4-carboxylic acid)-phenylboronic acid 
• 885068-69-9 4-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-tetrahydro-pyran-4-carboxylic acid 

Relevant articles and documents

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate

Structural modification of imidazole 5-lipoxygenase (5-LO) inhibitors for optimizing inhibitory potency, pharmacokinetic behavior and toxicity (ocular) profile led to 4-{3-[4-(2-methyl-1H-imidazol-1-yl)phenylthio]}phenyl-3,4,5,6- tetrahydro-2H-pyran-4-car